Novel approaches to targeting BRD4

O’Keefe, 2013, siRNAs and shRNAs: tools for protein knockdown by gene silencing, Mater Methods, 3, 197, 10.13070/mm.en.3.197 Mohr, 2014, RNAi screening comes of age: improved techniques and complementary approaches, Nat Rev Mol Cell Biol, 15, 591, 10.1038/nrm3860 Shi, 2014, The mechanisms behind the therapeutic activity of BET bromodomain inhibition, Mol Cell, 54, 728, 10.1016/j.molcel.2014.05.016 Filippakopoulos, 2014, Targeting bromodomains: epigenetic readers of lysine acetylation, Nat Rev Drug Discov, 13, 337, 10.1038/nrd4286 Noguchi-Yachide, 2016, Bromodomain as a target of epigenetic therapy, Chem Pharm Bull, 64, 540, 10.1248/cpb.c16-00225 Wang, 2015, Beating the odds: BETs in disease, Trends Biochem Sci, 40, 468, 10.1016/j.tibs.2015.06.002 Yan, 2016, Epigenome-based personalized medicine in human cancer, Epigenomics, 8, 119, 10.2217/epi.15.84 Von Schaper, 2016, Roche bets on bromodomains, Nat Biotechnol, 34, 361, 10.1038/nbt0416-361 Bui, 2016, The BET family bromodomain inhibitor ABBV-075 is a promising therapeutic agent for acute myeloid leukemia and myelodysplastic syndrome, A4738 Attwell, 2016, Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor in Phase I studies for Metastatic Castration-Resistant Prostate Cancer (mCRPC), LB-207 O’Dwyer, 2016, GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers, CT014 Liu, 2015, The BET inhibitor INCB054329 is efficacious as a single agent or in combination with targeted agents in colorectal cancer models, 3525 Shapiro, 2015, Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC), A49 Amorim, 2016, Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study, Lancet Haematol, 3, 196, 10.1016/S2352-3026(16)00021-1 Riveiro, 2016, OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations, Oncotarget, 3, 196 Stathis, 2016, Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628, Cancer Discov, 6, 492, 10.1158/2159-8290.CD-15-1335 Herait, 2015, BET- bromodomain (BRD) inhibitor OTX015: final results of the dose-finding part of a phase I study in hematologic malignancies, 13th International Congress on Targeted Anticancer Therapies Nakagawa, 2016, Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomains, Sci Rep, 6, 20390, 10.1038/srep20390 Newham, 2015 Bolden, 2014, Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition, Cell Rep, 8, 1919, 10.1016/j.celrep.2014.08.025 Massard, 2016, A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors, EORTC-NCI-AACR Huang, 2016, Drugging the undruggables: exploring the ubiquitin system for drug development, Cell Res, 26, 484, 10.1038/cr.2016.31 Buckley DL, Raina K, Darricarrere N, Hines J, Gustafson JL, Ian E. et al. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins 2015; 10(8): 1831–37. Bondeson, 2015, Catalytic in vivo protein knockdown by small-molecule PROTACs, Nat Chem Biol, 11, 611, 10.1038/nchembio.1858 Lu, 2015, Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4, Chem Biol, 22, 755, 10.1016/j.chembiol.2015.05.009 Raina, 2016, PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer, PNAS, 113, 7124, 10.1073/pnas.1521738113 Asangani, 2016, BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer, Mol Cancer Res, 14, 324, 10.1158/1541-7786.MCR-15-0472 Asangani, 2014, Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer, Nature, 510, 278, 10.1038/nature13229 Wyce, 2013, Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer, Oncotarget, 4, 2419, 10.18632/oncotarget.1572 Gao, 2013, Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation, PLoS One, 8, e63563, 10.1371/journal.pone.0063563 Galdeano, 2014, Structure-guided design and optimization of small molecules targeting the protein–protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the Hypoxia Inducible Factor (HIF) alpha subunit with in vitro nanomolar affinities, J Med Chem, 57, 8657, 10.1021/jm5011258 Winter, 2015, Phthalimide conjugation as a strategy for in vivo target protein degradation, Science, 348, 1376, 10.1126/science.aab1433 Zengerle, 2015, Selective small molecule induced degradation of the BET bromodomain protein BRD4, ACS Chem Biol, 10, 1770, 10.1021/acschembio.5b00216 Zhong, 2015, An iridium (III)-based irreversible protein–protein interaction inhibitor of BRD4 as a potent anticancer agent, Chem Sci, 6, 5400, 10.1039/C5SC02321A Winkler, 2016, PROTAC BET degraders are more broadly effective than BET inhibitors, EORTC-NCI-AACR, 15